Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)

European Journal of Cancer

Volumn 46, Issue 8, 2010, Pages 1344-1351

  Le Cesne, Axel ^a   Blay, Jean Yves ^b   Bui, Binh Nguyen ^c   Bouché, Olivier ^d   Adenis, Antoine ^e   Domont, Julien ^a   Cioffi, Angela ^a   Ray Coquard, Isabelle ^b   Lassau, Nathalie ^a   Bonvalot, Sylvie ^a   Moussy, Alain ^f   Kinet, Jean Pierre ^g   Hermine, Olivier ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c INSTITUT BERGONIÉ   (France)

^d SERVICE DE DERMATOLOGIE   (France)

^e CENTRE OSCAR LAMBRET   (France)

^f AB Science   (France)

^g HARVARD MEDICAL SCHOOL   (United States)

^h CNRS   (France)

Author keywords

c Kit; GIST; Imatinib; Locally advanced gastro intestinal stromal tumour; Masitinib; Metastatic gastro intestinal stromal tumour; Phase 2 study; Tyrosine kinase inhibitor

Indexed keywords

FLUORODEOXYGLUCOSE; IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; MASITINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR; THIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LACRIMATION; MALE; METABOLIC RATE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING; DISEASE FREE SURVIVAL; DOSE RESPONSE; FRANCE; GASTROINTESTINAL STROMAL TUMORS; GENETICS; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRANCE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME; BENZAMIDES;

EID: 77951878436     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.014     Document Type: Article

References (32)

1. Kindblom L.G., Remotti H.E., Aldenborg F., et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152 (1998) 1259-1269
2. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
3. Rubin B.P., Singer S., Tsao C., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61 (2001) 8118-8121
4. Wardelmann E., Losen I., Hans V., et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 106 (2003) 887-895
5. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
6. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med 347 (2002) 472-480
7. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 (2004) 1127-1134
8. Blanke C.D., Rankin C., Demetri G.D., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26 (2008) 626-632
9. Heinrich M.C., Corless C.L., Blanke C.D., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24 (2006) 4764-4774
10. Van Glabbeke M., Verweij A.M., Casali P.G., et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group Study. J Clin Oncol 23 (2005) 5795-5803
11. Zalcberg J.R., Verweij J., Casali P.G., et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41 (2005) 1751-1757
12. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
13. Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26 (2008) 620-625
14. Dubreuil P., Létard S., Ciufolini M.A., et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 4 9 (2009) e7258
15. Soria J.C., Massard C., Magne N., et al. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer 45 (2009) 2333-2341
16. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42 (2006) 1093-1103
17. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
18. Jager P.L., Gietema J.A., and van der Graaf W.T. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 25 (2004) 433-438
19. Blay J.Y., Le Cesne A., Ray-Coquard I., et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25 (2007) 1107-1113
20. Blay J.Y., Bonvalot S., Casali P., et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 16 (2005) 566-578
21. Van Glabbeke M, Owzar K, Rankin C, et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analysis based on 1640 patients (pts). J Clin Oncol 2007;25(Suppl 18S):10004.
22. Demetri G.D., Wang Y., Wehrle E., et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumor. J Clin Oncol 27 (2009) 3141-3147
23. Van Glabbeke M., Verweij J., Casali P.G., et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 42 (2006) 2277-2285
24. Tebib J., Mariette X., Bourgeois P., et al. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Therapy 11 (2009) R95
25. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25 (2007) 1753-1759
26. Lassau N., Lamuraglia M., Chami L., et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 187 (2006) 1267-1273
27. Prior J.O., Montemurro M., Orcurto M.V., et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 27 (2009) 439-445
28. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38(Suppl 5):S60-5.
29. Chami L., Lassau N., Koscielny, et al. Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in patients with GIST treated by tyrosine kinase inhibitor (TKI). J Clin Oncol 26 Suppl (2008) 10552
30. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. J Clin Oncol 25 (2007) 1760-1764
31. Le Cesne A., van Glabbeke M., Verweij J., et al. Absence of progression as assessed by RECIST predicts survival in advanced gastro-intestinal tumors (GIST) treated with imatinib mesylate: analysis of the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol 27 (2009) 3969-3974
32. Siesser P.M., and Hanks S.K. The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res 12 (2006) 3233-3237